Financial Analysis: Janux Therapeutics (NASDAQ:JANX) vs. Nuvation Bio (NYSE:NUVB)

Janux Therapeutics (NASDAQ:JANX) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Janux Therapeutics and Nuvation Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10.00 million	101.37	-$113.62 million	($1.64)	-10.11
Nuvation Bio	$62.90 million	31.40	-$204.63 million	($0.44)	-12.78

Janux Therapeutics has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Janux Therapeutics and Nuvation Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Volatility and Risk

Janux Therapeutics has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Janux Therapeutics and Nuvation Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2	2	10	1	2.67
Nuvation Bio	1	2	10	0	2.69

Janux Therapeutics presently has a consensus price target of $36.46, indicating a potential upside of 119.91%. Nuvation Bio has a consensus price target of $13.00, indicating a potential upside of 131.11%. Given Nuvation Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Janux Therapeutics.

Insider & Institutional Ownership

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Janux Therapeutics beats Nuvation Bio on 9 of the 14 factors compared between the two stocks.

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.